Karin Inger Martina Fahl Wader
Publikasjoner
2024
-
Jerkeman, Mats;
Kolstad, Arne;
Hutchings, Martin;
Pasanen, Annika;
Meriranta, Leo;
Niemann, Carsten Utoft.
(2024)
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.
Blood Advances
Vitenskapelig artikkel
2022
-
Riise, Jon;
Meyer, Saskia;
Blaas, Isaac;
Chopra, Adity;
Tran, Trung;
Delic-Sarac, Marina.
(2022)
Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination.
British Journal of Haematology
Vitenskapelig artikkel
2019
-
Lockmer, Sandra;
Østenstad, Bjørn;
Hagberg, Hans;
Holte, Harald;
Wahlin, Björn Engelbrekt;
Wader, Karin Fahl.
(2019)
Reply to M. Sorigue et al.
Journal of Clinical Oncology
Brev til redaktøren
2018
-
Lockmer, Sandra;
Østenstad, Bjørn;
Hagberg, Hans;
Holte, Harald;
Johansson, Ann-Sofie;
Wahlin, Björn Engelbrekt.
(2018)
Chemotherapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: Results from two Nordic lymphoma group trials with more than 10 years of follow-up.
Journal of Clinical Oncology
Vitenskapelig artikkel
-
Jerkeman, Mats;
Eskelund, Christian Winther;
Hutchings, Martin;
Räty, Riikka;
Wader, Karin Fahl;
Laurell, Anna.
(2018)
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
The Lancet Haematology
Vitenskapelig artikkel
2016
-
Nahi, Hareth;
Våtsveen, Thea Kristin;
Lund, Johan;
Heeg, Bart M.S.;
Preiss, Birgitte;
Alici, Evren.
(2016)
Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
European Journal of Haematology
Vitenskapelig artikkel
2015
-
Rustad, Even Holth;
Dai, Hong Yan;
Hov, Håkon;
Coward, Eivind;
Beisvag, Vidar;
Myklebost, Ola.
(2015)
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.
Blood Cancer Journal
Vitenskapelig artikkel
-
Kimby, Eva;
Østenstad, Bjørn;
Brown, Peter;
Hagberg, Hans;
Erlanson, Martin;
Holte, Harald.
(2015)
Two courses of four weekly infusions of rituximab with or without interferon-α2a: Final results from a randomized phase III study in symptomatic indolent B-cell lymphomas.
Leukemia and Lymphoma
Vitenskapelig artikkel
-
Olsen, Oddrun Elise;
Wader, Karin Fahl;
Hella, Hanne;
Mylin, Anne K.;
Turesson, Ingemar;
Nesthus, Ingerid.
(2015)
Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B.
Cell Communication and Signaling
Vitenskapelig artikkel
2014
-
Olsen, Oddrun Elise;
Wader, Karin Fahl;
Misund, Kristine;
Våtsveen, Thea Kristin;
Rø, Torstein Baade;
Mylin, Anne K..
(2014)
Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.
Blood Cancer Journal
Vitenskapelig artikkel
-
Slørdahl, Tobias Schmidt;
Wader, Karin Fahl;
Berntsen, Erik Magnus.
(2014)
Månedens billede.
Ugeskrift for Læger
Short communication
2012
-
Wader, Karin Fahl;
Fagerli, Unn-Merete;
Børset, Magne;
Lydersen, Stian;
Hov, Håkon;
Sundan, Anders.
(2012)
Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease.
Histopathology
Vitenskapelig artikkel
2011
-
Yri, Olav Erich;
Torfoss, Dag;
Hungnes, Olav;
Østenstad, Bjørn;
Ekanger, Roald;
Wader, Karin Fahl.
(2011)
LYMPHOMA PATIENTS TREATED WITH RITUXIMAB-CONTAINING REGIMENS DO NOT ACHIEVE PROTECTIVE SEROLOGICAL RESPONSES TO H1N1 INFLUENZA VIRUS AFTER VACCINATION.
Annals of Oncology
Sammendrag/abstract
-
Wader, Karin Fahl;
Fagerli, Unn-Merete;
Holt, Randi Utne;
Børset, Magne;
Sundan, Anders;
Waage, Anders.
(2011)
Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters.
European Journal of Haematology
Vitenskapelig artikkel
-
Yri, Olav Erich;
Torfoss, Dag;
Hungnes, Olav;
Tierens, Anne;
Waalen, Kristian;
Nordøy, Tone.
(2011)
Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment.
Blood
Vitenskapelig artikkel
2009
-
Wader, Karin Fahl;
Hov, H;
Brede, G;
Standal, T;
Martina, KI;
Borset, M.
(2009)
Syndecan-1 Mediates HGF/c-Met Endocytosis and Signaling in Myeloma Cells.
Clinical Lymphoma & Myeloma
Sammendrag/abstract
2008
-
Wader, Karin Fahl;
Fagerli, Unn Merete;
Holt, Randi Utne;
Børset, Magne;
Størdal, Berit Fladvad;
Sundan, Anders.
(2008)
Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma.
European Journal of Haematology
Vitenskapelig artikkel
-
Wader, Karin Fahl;
Fagerli, Unn-Merete;
Holt, Randi Utne;
Størdal, Berit Fladvad;
Børset, Magne;
Sundan, Anders.
(2008)
Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma.
European Journal of Haematology
Vitenskapelig artikkel
Tidsskriftspublikasjoner
-
Jerkeman, Mats;
Kolstad, Arne;
Hutchings, Martin;
Pasanen, Annika;
Meriranta, Leo;
Niemann, Carsten Utoft.
(2024)
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.
Blood Advances
Vitenskapelig artikkel
-
Riise, Jon;
Meyer, Saskia;
Blaas, Isaac;
Chopra, Adity;
Tran, Trung;
Delic-Sarac, Marina.
(2022)
Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination.
British Journal of Haematology
Vitenskapelig artikkel
-
Lockmer, Sandra;
Østenstad, Bjørn;
Hagberg, Hans;
Holte, Harald;
Wahlin, Björn Engelbrekt;
Wader, Karin Fahl.
(2019)
Reply to M. Sorigue et al.
Journal of Clinical Oncology
Brev til redaktøren
-
Lockmer, Sandra;
Østenstad, Bjørn;
Hagberg, Hans;
Holte, Harald;
Johansson, Ann-Sofie;
Wahlin, Björn Engelbrekt.
(2018)
Chemotherapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: Results from two Nordic lymphoma group trials with more than 10 years of follow-up.
Journal of Clinical Oncology
Vitenskapelig artikkel
-
Jerkeman, Mats;
Eskelund, Christian Winther;
Hutchings, Martin;
Räty, Riikka;
Wader, Karin Fahl;
Laurell, Anna.
(2018)
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
The Lancet Haematology
Vitenskapelig artikkel
-
Nahi, Hareth;
Våtsveen, Thea Kristin;
Lund, Johan;
Heeg, Bart M.S.;
Preiss, Birgitte;
Alici, Evren.
(2016)
Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
European Journal of Haematology
Vitenskapelig artikkel
-
Rustad, Even Holth;
Dai, Hong Yan;
Hov, Håkon;
Coward, Eivind;
Beisvag, Vidar;
Myklebost, Ola.
(2015)
BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.
Blood Cancer Journal
Vitenskapelig artikkel
-
Kimby, Eva;
Østenstad, Bjørn;
Brown, Peter;
Hagberg, Hans;
Erlanson, Martin;
Holte, Harald.
(2015)
Two courses of four weekly infusions of rituximab with or without interferon-α2a: Final results from a randomized phase III study in symptomatic indolent B-cell lymphomas.
Leukemia and Lymphoma
Vitenskapelig artikkel
-
Olsen, Oddrun Elise;
Wader, Karin Fahl;
Hella, Hanne;
Mylin, Anne K.;
Turesson, Ingemar;
Nesthus, Ingerid.
(2015)
Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B.
Cell Communication and Signaling
Vitenskapelig artikkel
-
Olsen, Oddrun Elise;
Wader, Karin Fahl;
Misund, Kristine;
Våtsveen, Thea Kristin;
Rø, Torstein Baade;
Mylin, Anne K..
(2014)
Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin.
Blood Cancer Journal
Vitenskapelig artikkel
-
Slørdahl, Tobias Schmidt;
Wader, Karin Fahl;
Berntsen, Erik Magnus.
(2014)
Månedens billede.
Ugeskrift for Læger
Short communication
-
Wader, Karin Fahl;
Fagerli, Unn-Merete;
Børset, Magne;
Lydersen, Stian;
Hov, Håkon;
Sundan, Anders.
(2012)
Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease.
Histopathology
Vitenskapelig artikkel
-
Yri, Olav Erich;
Torfoss, Dag;
Hungnes, Olav;
Østenstad, Bjørn;
Ekanger, Roald;
Wader, Karin Fahl.
(2011)
LYMPHOMA PATIENTS TREATED WITH RITUXIMAB-CONTAINING REGIMENS DO NOT ACHIEVE PROTECTIVE SEROLOGICAL RESPONSES TO H1N1 INFLUENZA VIRUS AFTER VACCINATION.
Annals of Oncology
Sammendrag/abstract
-
Wader, Karin Fahl;
Fagerli, Unn-Merete;
Holt, Randi Utne;
Børset, Magne;
Sundan, Anders;
Waage, Anders.
(2011)
Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters.
European Journal of Haematology
Vitenskapelig artikkel
-
Yri, Olav Erich;
Torfoss, Dag;
Hungnes, Olav;
Tierens, Anne;
Waalen, Kristian;
Nordøy, Tone.
(2011)
Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment.
Blood
Vitenskapelig artikkel
-
Wader, Karin Fahl;
Hov, H;
Brede, G;
Standal, T;
Martina, KI;
Borset, M.
(2009)
Syndecan-1 Mediates HGF/c-Met Endocytosis and Signaling in Myeloma Cells.
Clinical Lymphoma & Myeloma
Sammendrag/abstract
-
Wader, Karin Fahl;
Fagerli, Unn Merete;
Holt, Randi Utne;
Børset, Magne;
Størdal, Berit Fladvad;
Sundan, Anders.
(2008)
Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma.
European Journal of Haematology
Vitenskapelig artikkel
-
Wader, Karin Fahl;
Fagerli, Unn-Merete;
Holt, Randi Utne;
Størdal, Berit Fladvad;
Børset, Magne;
Sundan, Anders.
(2008)
Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma.
European Journal of Haematology
Vitenskapelig artikkel
Formidling
2016
-
PosterOlsen, Oddrun Elise; Wader, Karin Fahl; Hella, Hanne; Waage, Anders; Sundan, Anders; Holien, Toril. (2016) Activin A inhibits BMP-signalling by binding ACVR2A and ACVR2B. The Biochemical Society, UK BMP Signalling in Cancer , Cambridge 2016-03-15 - 2016-03-17
2015
-
PosterOlsen, Oddrun Elise; Wader, Karin Fahl; Hella, Hanne; Waage, Anders; Sundan, Anders; Holien, Toril. (2015) Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B. FASEB The TGFb Superfamily: Signaling in Development and Disease 2015-07-12 - 2015-07-17
2013
-
PosterOlsen, Oddrun Elise; Wader, Karin Fahl; Misund, Kristine; Våtsveen, Thea Kristin; Rø, Torstein Baade; Størdal, Berit Fladvad. (2013) Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. FASEB TGF-B Superfamily: Signaling in Development and Disease 2013-07-28 - 2013-08-02
-
Faglig foredragOlsen, Oddrun Elise; Wader, Karin Fahl; Misund, Kristine; Våtsveen, Thea Kristin; Rø, Torstein Baade; Størdal, Berit Fladvad. (2013) Membrane bound and soluble endoglin protects myeloma cells from bone morphogenetic protein 9 induced apoptosis. NBS vintermøte 2013-01-17 - 2013-01-20
2011
-
PosterVåtsveen, Thea Kristin; Wader, Karin Fahl; Grøseth, Lill Anny Gunnes; Sundan, Anders; Aarset, Harald; Hong Yan, Dai. (2011) Multiple Myeloma Patients- a prospective study based on interphase-FISH on newly diagnosed patiens from 2006-2010. Gordon Research Gordon Research Confrence , Ventura, CA 2011-01-23 - 2011-01-28
2008
-
Vitenskapelig foredragWader, Karin Fahl. (2008) Immunohistochemical analysis of HGF and c. Met in plasma cell disease. IKM Tirsdagsmøte for DMF, NTNU og St. Olavs Hospital , Trondheim 2008-04-29 -
2007
-
Vitenskapelig foredragWader, Karin Fahl. (2007) Immunohistochemical analysis of HGF and c-Met in plasma cell disease. Institutt for kreftforskning og molekylær medisin, DMF, NTNU Tirsdagsmøte, Institutt for kreftforskning og molekylær medisin , Trondheim 2007-11-27 - 2007-11-27